Vincristine is used in the treatment of leukemias, solid tumors, and lymphomas. A case of a 2-year-old boy undergoing treatment for leukemia who developed sudden onset bilateral ptosis and ophthalmoplegia along with generalized neuropathy due to vincristine's neurotoxic effects is presented. He was successfully treated with pyridoxine and pyridostigmine. The possible mechanisms of action and the treatment for vincristine-induced neuropathy are discussed. Prompt treatment and close follow-up is needed, especially in children because prolonged ptosis and motility restriction may have a profound effect on a child's visual function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/01913913-20150629-01 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intestinal Pseudo-Obstruction After Vincristine Use.
Cureus
November 2024
Department of Intensive Care Medicine, Centro Hospitalar Universitário de São João, Porto, PRT.
A 73-year-old man presented with nausea, abdominal discomfort, and distention persisting for the past five days. He had previously been diagnosed with stage III peripheral CD4+ T cell lymphoma and had initiated chemotherapy comprising vincristine two weeks prior to presentation. An evaluation revealed diffuse colon distention and pneumatosis intestinalis without mechanical obstruction, consistent with acute colonic pseudo-obstruction.
View Article and Find Full Text PDFEthanolic Extracts of Linn. (Vitaceae) Attenuate Vincristine-Induced Peripheral Neuropathy in Rats: An Evidence of the Antioxidant, Calcium Inhibitory, and Neuromodulatory Properties.
Adv Pharmacol Pharm Sci
December 2024
Laboratory of Animal Physiology and Phytopharmacology, Department of Animal Biology, Faculty of Science, University of Dschang, Dschang, Cameroon.
Linn. (, Vitaceae) is a plant reported to treat injured tendons, broken bones, asthma, stomach ache, scurvy, and digestive disorders. The present study evaluated the antihyperalgesic effects of ethanolic extract of Linn.
View Article and Find Full Text PDFNerve cross-sectional area in vincristine-induced polyneuropathy: A nerve ultrasound pilot study.
J Neuroimaging
December 2024
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Article Synopsis
- The study investigates the effectiveness of high-resolution nerve ultrasound (HRUS) in diagnosing polyneuropathy caused by the chemotherapy drug vincristine.
- Twelve patients undergoing vincristine treatment and twelve healthy controls participated, with measurements taken at various intervals, including nerve cross-sectional areas (CSAs), neuropathy scores, and nerve conduction studies.
- Results indicated that while overall CSA at nerve entrapment sites increased alongside clinical symptoms, HRUS did not show significant changes at individual nerve sites, highlighting that clinical exams are key for early detection of vincristine-induced polyneuropathy.
Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.
Life (Basel)
November 2024
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Vincristine, a vinca alkaloid, is used in chemotherapy protocols for cancers such as acute leukemia, Hodgkin's disease, neuroblastoma, cervical carcinoma, lymphomas, breast cancer, and melanoma. Among the common adverse effects of vincristine is peripheral neuropathy, with most patients receiving a cumulative dose over 4 mg/m who develop varying degrees of sensory neuropathy. The onset of vincristine-induced peripheral neuropathy can greatly affect patients' quality of life, often requiring dose adjustments or the discontinuation of treatment.
View Article and Find Full Text PDFGenomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients.
NPJ Genom Med
November 2024
Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vincristine-induced peripheral neuropathy is a common and highly debilitating toxicity from vincristine treatment that affects quality of life and often requires dose reduction, potentially affecting survival. Although previous studies demonstrated genetic factors are associated with vincristine neuropathy risk, the clinical relevance of most identified variants is limited by small sample sizes and unclear clinical phenotypes. A genome-wide association study was conducted in 1100 cases and controls matched by vincristine dose and genetic ancestry, uncovering a statistically significant (p < 5.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!